From policy to action: how to operationalize the treatment for all agenda

The 2015 World Health Organization (WHO) guidelines recommend antiretroviral treatment (ART) for all people living with HIV, regardless of CD4 count. Treatment for all (TfA) represents a significant step towards meeting the ambitious United Nations’ 90–90–90 target by 2020 and ending AIDS by 2030 [1]. Achieving these goals will require focused, multilateral efforts. Globally, only 54% of people living with HIV are now aware of their HIV status and only 41% of adults and 32% of children diagnosed with HIV are on ART [2]. It is, therefore, clear that we are far from realizing the full benefits of ART, and substantial efforts will be needed to meet the 90–90–90 target. To move from policy to action and achieve TfA, we urgently need to renew our operational agenda. We must rapidly expand access to and uptake of comprehensive HIV services while introducing efficiencies and new models of care that will enable overburdened health systems to sustain current patients while accelerating intake of new patients. This strategy must be based on realities on the ground and be designed to 1) make care simpler and more accessible, 2) create rational models of care that are responsive to patients’ needs and 3) identify and implement transformative tools to reach TfA. This article proposes the development and adoption of a differentiated care model as a practical approach to reach TfA and accelerate progress towards the 90–90–90 target. Efficient approaches to HIV testing, tailored to client values and preferences, have increased the detection of HIV infection. For example, several large community-based HIV testing studies have shown acceptance rates of 80% or greater, linkage to care of 80% and eventual treatment initiation of 73% [3]. The Accept project, a cluster-randomized trial, demonstrated that widespread community mobilization and provision of mobile testing services were associated with a 14% fall in HIV incidence [4]. Two large multi-disease prevention campaigns, in Kenya and Uganda, showed high uptake of HIV testing [5]. In a Malawian study, 75% of people took an annual self-test, and more than half of those diagnosed were linked to HIV care [6]. Addressing the testing needs of vulnerable and priority populations may also result in increased testing yield and linkage to care. Men – who access the health system less frequently than women – are tested in higher numbers when HIV testing is offered at work sites as compared to HIV testing clinics (e.g. 51.1% vs. 19.2%) [7, 8]. And, although the evidence is limited, provider-initiated testing and counselling of children in key health service entry points have shown an average yield of 16.6%, with paediatric inpatient units showing 22.5% [9]. A number of evidence-based interventions have demonstrated success in simplifying ART initiation and treatment. Nurse-initiated and managed ART has been shown to be as or more effective at reducing mortality and achieving undetectable viral load when compared with standard physician-initiated ART care [10, 11]. The 2015 WHO guidelines recommend spacing visits once every three to six months and dropping CD4 testing for patients who are stable and virologically suppressed on ART [12–14]. Members of community-based adherence clubs and community ART groups, and recipients of community ART distribution, achieve equal or higher levels of retention in care and viral load suppression as compared to facility-based patients [15–18]. Routine viral load monitoring can be used in a cost-effective way to identify stable, virologically suppressed patients for whom care can be streamlined, including through community-managed care [19]. Paediatric patients also do well in decentralized care models, with one cohort study of community-based versus facility-based care showing no significant difference in survival rates and improved retention for community-based versus facility-based care (94.8% vs. 84.7%) [20]. These interventions also lower costs to the healthcare system [21] and will simplify management, help normalize the lives of patients on ART and make use of available resources more efficiently. As a significant loss to follow-up (32–54%) occurs in the period before ART initiation [22, 23], reducing pre-ART time has helped increase retention. New data show that same-day initiation results in higher retention [24, 25]. Other simple interventions improve retention after ART initiation. Home-based visits by community health workers soon after ART initiation can help decrease early loss to follow-up after ART initiation [26]. Reminders sent via short message service (SMS) to cell phones result in significantly higher adherence for patients on ART [27, 28]. The TfA approach is not new. Since 2003, the Government of British Columbia has progressively expanded access to ART. In 2009, the province formalized a universal, fully funded TfA policy, known as Seek and Treat for Optimal Prevention of HIV/AIDS. This policy has been associated with marked and steady decreases in AIDS-related incidence, morbidity and mortality [29]. Similarly, the University of California, San Francisco/San Francisco General Hospital RAPID programme offers immediate access to ART on the same day as HIV diagnosis. Under this initiative, ART uptake has quadrupled and viral load suppression has doubled [30]. Encouragingly, comparable trends are emerging in limited resource settings. A study in KwaZulu-Natal, South Africa, has reported that an increase in ART coverage of 1% was associated with a 1% decrease in new HIV infections [31]. In programmes like these, even when initiating asymptomatic patients at higher CD4 counts, adherence levels remain high [32]. Another promising TfA strategy is Option B+, universal offer of lifelong ART to all HIV-positive pregnant and lactating women. The Elizabeth Glaser Pediatric AIDS Foundation has supported the rollout of Option B+ programmes in 12 countries since 2011 and shown that initiating ART regardless of CD4 count is feasible and effective in resources-constrained settings. It has also demonstrated the need to change the current system to enable earlier identification of patients and retention of large numbers of healthy patients in quality care. In fact, many women still presented late, with HIV Stage III or IV disease. Further, only 74% of women on ART (excluding transfer outs) were retained in care at 12 months in Malawi [33]. TfA will require a comprehensive package of differentiated testing, care and treatment fit to different contexts and needs of different patient populations, including children and adolescents. Therefore, we must support decentralization and simplification at the individual and programmatic level for stable, suppressed individuals and for well-functioning programmes. We must also employ patient- and programme-level data to identify and act upon unstable, poorly functioning and immature programmes. A differentiated package of care should include proven interventions, tools and models to generate the greatest efficiencies and ensure maximum returns from limited healthcare resources. It will also be critical that these interventions are not only acceptable to but also desired by patients and communities. The proposed package (Figure 1) highlights breakpoints that may be used to support differentiated care. The interventions described may be considered a basic package; new tools and other innovative models of care should be considered, piloted and – if effective – scaled up. These might include detecting acute HIV infection using point-of-care viral load monitoring; collecting viral load samples at very decentralized facilities via dried blood spots, with results returned by SMS; or adopting optimized treatment, including long-acting injectable ART for key populations. Proposed standard package of interventions for differentiated care. Use of standard packages to optimize differentiated care must be field-tested for feasibility and impact on the achievement of TfA. Successful implementation of these packages will also be dependent on 1) the placement of policies that enable task shifting; 2) the development of metrics that reflect progress towards the 90–90–90 and assess the impact of the differentiated package of care; 3) the existence of sufficient programmatic infrastructure, including procurement and supply chains; and 4) support of sentinel sites to monitor transmitted and acquired drug resistance and to inform future first-line ART [34] – especially in light of growing non-nucleoside reverse-transcriptase inhibitors [35] resistance and higher-than-expected tenofovir disoproxil fumarate [36] resistance. As the TfA approach progresses globally, HIV epidemiology will evolve, resulting in larger cohorts of stable, virologically suppressed patients and a decrease in HIV incidence. A more simplified approach for the management of these stable cohorts will be possible, and a different strategy and treatment approach may be required. Both the health system and the patients in these stable cohorts will benefit from a pathway that includes fewer clinic visits, streamlined and community-based drug distribution and reduced laboratory monitoring requirements. Over time, the authors feel that normalizing TfA, identifying and treating patients earlier in the disease to keep them healthy and simplifying care by allowing community-based care will help reduce the stigma associated with HIV. Although TfA will generate long-term benefits and reduce costs overall, the strategy will initially require increased political and financial capital [37]. Accept that excellent care can be algorithmic and performed by healthcare workers with limited training Allow stable, undetectable patients in treatment to manage their own care by accessing community-based care and reducing clinic visits Assess and pilot innovative tools and models of care Exchange CD4 monitoring for viral load monitoring Normalize and integrate ART through service provider education on the benefits of TfA and multi-disease programming that includes ART initiation and support alongside other primary health interventions such as hypertension screening or blood glucose testing Support operational research on various packages of differentiated care to better define the impact, feasibility and cost-effectiveness of various models and expand the evidence supporting this promising model of care Provide appropriate investment in such models of care to reach TfA To virtually end AIDS by 2030, a collective investment has to take place now, using our most effective tools, policies, strategies and resources to operationalize TfA. The authors acknowledge the Elizabeth Glaser Pediatric AIDS Foundation for providing funding for this study. All authors declare they have no competing intersts. All authors certify that they have participated sufficiently in the writing of this article and take responsbility for the content included. All authors have read and approved the final version.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.